This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Resumen de acción SESN
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Sesen Bio, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.58 |
| 52 Week High | US$19.30 |
| 52 Week Low | US$7.30 |
| Beta | 0.83 |
| 1 Month Change | 8.32% |
| 3 Month Change | 21.04% |
| 1 Year Change | -7.05% |
| 3 Year Change | -12.67% |
| 5 Year Change | -45.32% |
| Change since IPO | -94.20% |
Noticias y actualizaciones recientes
Recent updates
Sesen Bio and Carisma Therapeutics announce merger agreement
Sep 21Sesen Bio GAAP EPS of -$0.16 misses by $0.03
Aug 08Sesen Bio granted additional time period for regaining compliance
Jul 27Sesen Bio slips after decision to pause U.S. studies for lead asset
Jul 18Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
Jun 02We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
Apr 17
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
Dec 05Sesen Bio: Interesting Price Drop After CRL
Nov 24Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
Nov 17Sesen Bio: The Road Ahead
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00
Aug 12Sesen Bio: Binary Event Approaching
Jun 13Sesen Bio inks global supply partnership with Qilu Pharmaceutical
Jun 02Sesen Bio EPS misses by $0.27
May 10Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
May 07News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat
Feb 18Sesen announces positive FDA meeting for vicineum's marketing application
Feb 01Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
Jan 26Sesen Bio/Qilu Pharma's Vicineum IND application accepted for review in China
Jan 13Sesen Bio files US application for its Vicineum in bladder cancer
Dec 21Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook
Dec 21
Sesen Bio: A Look At Vicineum's Potential
Nov 29Sesen Bio, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 09Rentabilidad de los accionistas
| SESN | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 6.5% | -2.5% | -3.2% |
| 1Y | -7.1% | -3.7% | 19.3% |
Rentabilidad vs. Industria: SESN underperformed the US Biotechs industry which returned 4.3% over the past year.
Rentabilidad vs. Mercado: SESN exceeded the US Market which returned -8.5% over the past year.
Volatilidad de los precios
| SESN volatility | |
|---|---|
| SESN Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: SESN has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: SESN's weekly volatility (9%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2008 | 17 | Thomas Cannell | sesenbio.com |
Resumen de fundamentos de Sesen Bio, Inc.
| Estadísticas fundamentales de SESN | |
|---|---|
| Capitalización bursátil | US$2.56b |
| Beneficios(TTM) | -US$19.88m |
| Ingresos (TTM) | US$40.00m |
64.0x
Ratio precio-ventas (PS)-128.7x
Ratio precio-beneficio (PE)¿Está SESN sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de SESN | |
|---|---|
| Ingresos | US$40.00m |
| Coste de los ingresos | US$1.99m |
| Beneficio bruto | US$38.02m |
| Otros gastos | US$57.90m |
| Beneficios | -US$19.88m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.098 |
| Margen bruto | 95.04% |
| Margen de beneficio neto | -49.71% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado SESN a largo plazo?
Ver rendimiento histórico y comparativa